Taysha Gene Therapies, Inc.

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

Early data from Neurogene’s Phase I/II trial of NGN-401 in Rett syndrome look promising, but it remains unclear how differentiated they are from competitor Taysha Gene Therapy’s TSHA-102, being develo

The Foundation for the National Institutes of Health’s Bespoke Gene Therapy Consortium is offering a regulatory guidebook to help investigators navigate the investigational new drug application submis

While 2023 saw several cell and gene therapy approvals that were genuine scientific and clinical breakthroughs, many smaller companies in the sector bore the brunt of the ongoing biopharma downturn. M